News and Media

2015/04/15 – Quantum Genomics to meet investors at the European Smallcap Event, April 27 & 28, 2015

16 April 2015
|

Quantum Genomics (Alternext – FR0011648971 – ALQGC), ), a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, will be participating at the 10th edition of the European Smallcap Event, a conference dedicated to meetings between European […]

2015/03/17 – Creation of a joint Inserm-Quantum Genomics laboratory at the Collège de France backed by the French National Agency for Research (ANR)

17 March 2015
|

Quantum Genomics (Alternext – FR0011648971 – ALQGC), ), a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, announces the creation of a joint laboratory with the INSERM laboratory led by Catherine Llorens-Cortes at the Coll […]

2015/03/03 : First patients recruited for Phase IIa trial of drug candidate QGC001

3 March 2015
|

Quantum Genomics (Alternext – FR0011648971 – ALQGC), a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, announces it has now recruited the first three patients for its Phase IIa trial of its molecule QGC001.

This first-in […]

Quantum Genomics reports total capital increase after stabilization period: €12.9 million

25 February 2015
|

Quantum Genomics (Alternext – FR0011648971 – ALQGC), a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, announces that broking firm Invest Securities, as Lead Manager and Bookrunner, has informed the Company that the overallotment option, granted to it as […]